Calidi Biotherapeutics (CLDI) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.8 million vs $1.6 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | SCNI |
|---|---|---|
| Share price | $1.03 | $1.18 |
| Market cap | $3.79M | $1.60M |
| 1-day change | -0.96% | -2.48% |
| P/E ratio (TTM) | — | 0.04 |
| EPS (TTM) | $-36.47 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $15.65 |
| 52-week low | $0.986 | $1.06 |
| Distance from 52-week high | -96.30% | -92.46% |
| Average volume | 255.53K | 1.10M |
| Shares outstanding | 3.68M | 1.35M |
| Employees | 29 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Calidi Biotherapeutics is about 2.4 times larger than Scinai Immunotherapeutics by market value ($3.79M vs $1.60M).
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
CLDI vs SCNI FAQ
Which is bigger, Calidi Biotherapeutics or Scinai Immunotherapeutics?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.79M compared with $1.60M for Scinai Immunotherapeutics (SCNI).
Are Calidi Biotherapeutics and Scinai Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.